Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds

Table of Contents

June 1, 2022; Volume 63,Issue 6

This Month in JNM

  • You have access
    This Month in JNM
    Journal of Nuclear Medicine June 1, 2022, 63 (6) 10A;

Editor's Page

  • You have access
    How Many Theranostics Centers Will We Need in the United States?
    Johannes Czernin and Jeremie Calais
    Journal of Nuclear Medicine June 1, 2022, 63 (6) 805-806; DOI: https://doi.org/10.2967/jnumed.122.264144

Commentary

  • You have access
    A Letter from Ukraine
    Ken Herrmann and Kmetyuk Yaroslav
    Journal of Nuclear Medicine June 1, 2022, 63 (6) 807; DOI: https://doi.org/10.2967/jnumed.122.264288

Discussions with Leaders

  • You have access
    Precision Medicine Clinical Trials
    Peter J. O’Dwyer and Lale Kostakoglu
    Journal of Nuclear Medicine June 1, 2022, 63 (6) 808-811; DOI: https://doi.org/10.2967/jnumed.121.264320

Issues and Controversies

  • You have access
    The VISION Forward: Recognition and Implication of PSMA−/18F-FDG+ mCRPC
    Hossein Jadvar
    Journal of Nuclear Medicine June 1, 2022, 63 (6) 812-815; DOI: https://doi.org/10.2967/jnumed.121.263274

Editorial

  • You have access
    Why We Did What We Did: PSMA PET/CT Selection Criteria for the VISION Trial
    Phillip H. Kuo, Taylor Benson, Richard Messmann and Michael Groaning
    Journal of Nuclear Medicine June 1, 2022, 63 (6) 816-818; DOI: https://doi.org/10.2967/jnumed.121.263638

The State of The Art

  • You have access
    The Importance of Training, Accreditation, and Guidelines for the Practice of Theranostics: The Australian Perspective
    Sze Ting Lee, Louise M. Emmett, David A. Pattison, Michael S. Hofman, Dale L. Bailey, Melissa J. Latter, Roslyn J. Francis and Andrew M. Scott
    Journal of Nuclear Medicine June 1, 2022, 63 (6) 819-822; DOI: https://doi.org/10.2967/jnumed.122.263996

Continuing Education

  • You have access
    Prostate Cancer Treatment: 177Lu-PSMA-617 Considerations, Concepts, and Limitations
    Oliver Sartor and Ken Herrmann
    Journal of Nuclear Medicine June 1, 2022, 63 (6) 823-829; DOI: https://doi.org/10.2967/jnumed.121.262413

Hot Topics

  • You have access
    Tau Beats Amyloid in Predicting Brain Atrophy in Alzheimer Disease: Implications for Prognosis and Clinical Trials
    Maura Malpetti, Renaud La Joie and Gil D. Rabinovici
    Journal of Nuclear Medicine June 1, 2022, 63 (6) 830-832; DOI: https://doi.org/10.2967/jnumed.121.263694

Theranostics

  • Clinical

    • Pretherapeutic Comparative Dosimetry of <sup>177</sup>Lu-rhPSMA-7.3 and <sup>177</sup>Lu-PSMA I&amp;T in Patients with Metastatic Castration-Resistant Prostate Cancer
      You have access
      Pretherapeutic Comparative Dosimetry of 177Lu-rhPSMA-7.3 and 177Lu-PSMA I&T in Patients with Metastatic Castration-Resistant Prostate Cancer
      Benedikt Feuerecker, Maythinee Chantadisai, Anne Allmann, Robert Tauber, Jakob Allmann, Lisa Steinhelfer, Isabel Rauscher, Alexander Wurzer, Hans-Jürgen Wester, Wolfgang A. Weber, Calogero d’Alessandria and Matthias Eiber
      Journal of Nuclear Medicine June 1, 2022, 63 (6) 833-839; DOI: https://doi.org/10.2967/jnumed.121.262671
    • Effects of <sup>225</sup>Ac-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis
      You have access
      Effects of 225Ac-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis
      Dong Yun Lee and Yong-il Kim
      Journal of Nuclear Medicine June 1, 2022, 63 (6) 840-846; DOI: https://doi.org/10.2967/jnumed.121.262017
    • FEATURED ARTICLE OF THE MONTH

      • Head-to-Head Comparison of <sup>68</sup>Ga-PSMA-11 PET/CT and mpMRI with a Histopathology Gold Standard in the Detection, Intraprostatic Localization, and Determination of Local Extension of Primary Prostate Cancer: Results from a Prospective Single-Center Imaging Trial
        You have access
        Head-to-Head Comparison of 68Ga-PSMA-11 PET/CT and mpMRI with a Histopathology Gold Standard in the Detection, Intraprostatic Localization, and Determination of Local Extension of Primary Prostate Cancer: Results from a Prospective Single-Center Imaging Trial
        Ida Sonni, Ely R. Felker, Andrew T. Lenis, Anthony E. Sisk, Shadfar Bahri, Martin Allen-Auerbach, Wesley R. Armstrong, Voraparee Suvannarerg, Teeravut Tubtawee, Tristan Grogan, David Elashoff, Matthias Eiber, Steven S. Raman, Johannes Czernin, Robert E. Reiter and Jeremie Calais
        Journal of Nuclear Medicine June 1, 2022, 63 (6) 847-854; DOI: https://doi.org/10.2967/jnumed.121.262398
    • SPECIAL CONTRIBUTION

      • You have access
        18F-DCFPyL PET Acquisition, Interpretation, and Reporting: Suggestions After Food and Drug Administration Approval
        Hong Song, Andrei Iagaru and Steven P. Rowe
        Journal of Nuclear Medicine June 1, 2022, 63 (6) 855-859; DOI: https://doi.org/10.2967/jnumed.121.262989
  • Translational

    • INVITED PERSPECTIVE

      • You have access
        PET with a 68Ga-Labeled FAPI Dimer: Moving Toward Theranostics
        Muhsin H. Younis, Xiaoli Lan and Weibo Cai
        Journal of Nuclear Medicine June 1, 2022, 63 (6) 860-861; DOI: https://doi.org/10.2967/jnumed.121.263292
    • Synthesis, Preclinical Evaluation, and a Pilot Clinical PET Imaging Study of <sup>68</sup>Ga-Labeled FAPI Dimer
      Open Access
      Synthesis, Preclinical Evaluation, and a Pilot Clinical PET Imaging Study of 68Ga-Labeled FAPI Dimer
      Liang Zhao, Bo Niu, Jianyang Fang, Yizhen Pang, Siyang Li, Chengrong Xie, Long Sun, Xianzhong Zhang, Zhide Guo, Qin Lin and Haojun Chen
      Journal of Nuclear Medicine June 1, 2022, 63 (6) 862-868; DOI: https://doi.org/10.2967/jnumed.121.263016

Oncology

  • Clinical

    • Diagnostic Performance of <sup>124</sup>I-Metaiodobenzylguanidine PET/CT in Patients with Pheochromocytoma
      You have access
      Diagnostic Performance of 124I-Metaiodobenzylguanidine PET/CT in Patients with Pheochromocytoma
      Manuel Weber, Jochen Schmitz, Ines Maric, Kim Pabst, Lale Umutlu, Martin Walz, Ken Herrmann, Christoph Rischpler, Frank Weber, Walter Jentzen, Sarah Theurer, Thorsten D. Poeppel, Nicole Unger and Wolfgang P. Fendler
      Journal of Nuclear Medicine June 1, 2022, 63 (6) 869-874; DOI: https://doi.org/10.2967/jnumed.121.262797
    • The Added Value of <sup>68</sup>Ga-FAPI PET/CT in Patients with Head and Neck Cancer of Unknown Primary with <sup>18</sup>F-FDG–Negative Findings
      Open Access
      The Added Value of 68Ga-FAPI PET/CT in Patients with Head and Neck Cancer of Unknown Primary with 18F-FDG–Negative Findings
      Bingxin Gu, Xiaoping Xu, Ji Zhang, Xiaomin Ou, Zuguang Xia, Qing Guan, Silong Hu, Zhongyi Yang and Shaoli Song
      Journal of Nuclear Medicine June 1, 2022, 63 (6) 875-881; DOI: https://doi.org/10.2967/jnumed.121.262790
    • Pretreatment Levels of Soluble Tumor Necrosis Factor Receptor 1 and Hepatocyte Growth Factor Predict Toxicity and Overall Survival After <sup>90</sup>Y Radioembolization: Potential Novel Application of Biomarkers for Personalized Management of Hepatotoxicity
      You have access
      Pretreatment Levels of Soluble Tumor Necrosis Factor Receptor 1 and Hepatocyte Growth Factor Predict Toxicity and Overall Survival After 90Y Radioembolization: Potential Novel Application of Biomarkers for Personalized Management of Hepatotoxicity
      Matthew M. Cousins, Theresa P. Devasia, Christopher M. Maurino, Justin Mikell, Matthew J. Schipper, Ravi K. Kaza, Theodore. S. Lawrence, Kyle C. Cuneo and Yuni K. Dewaraja
      Journal of Nuclear Medicine June 1, 2022, 63 (6) 882-889; DOI: https://doi.org/10.2967/jnumed.121.262447
    • Pitfalls and Common Findings in <sup>68</sup>Ga-FAPI PET: A Pictorial Analysis
      You have access
      Pitfalls and Common Findings in 68Ga-FAPI PET: A Pictorial Analysis
      Lukas Kessler, Justin Ferdinandus, Nader Hirmas, Fadi Zarrad, Michael Nader, David Kersting, Manuel Weber, Sandra Kazek, Miriam Sraieb, Rainer Hamacher, Katharina Lueckerath, Lale Umutlu, Wolfgang P. Fendler and Christoph Rischpler
      Journal of Nuclear Medicine June 1, 2022, 63 (6) 890-896; DOI: https://doi.org/10.2967/jnumed.121.262808
    • INVITED PERSPECTIVE

      • You have access
        Imaging PD-L1 Expression in Melanoma Brain Metastases
        Sridhar Nimmagadda
        Journal of Nuclear Medicine June 1, 2022, 63 (6) 897-898; DOI: https://doi.org/10.2967/jnumed.121.263209
    • <sup>18</sup>F-BMS986192 PET Imaging of PD-L1 in Metastatic Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors: A Pilot Study
      Open Access
      18F-BMS986192 PET Imaging of PD-L1 in Metastatic Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors: A Pilot Study
      Pieter H. Nienhuis, Inês F. Antunes, Andor W.J.M. Glaudemans, Mathilde Jalving, David Leung, Walter Noordzij, Riemer H.J.A. Slart, Erik F.J. de Vries and Geke A.P. Hospers
      Journal of Nuclear Medicine June 1, 2022, 63 (6) 899-905; DOI: https://doi.org/10.2967/jnumed.121.262368
    • <sup>18</sup>F-FDG PET/CT for Posttreatment Surveillance Imaging of Patients with Stage III Merkel Cell Carcinoma
      You have access
      18F-FDG PET/CT for Posttreatment Surveillance Imaging of Patients with Stage III Merkel Cell Carcinoma
      Sonia Mahajan, Christopher A. Barker, Audrey Mauguen, Sandra P. D’Angelo, Randy Yeh and Neeta Pandit-Taskar
      Journal of Nuclear Medicine June 1, 2022, 63 (6) 906-911; DOI: https://doi.org/10.2967/jnumed.121.262882
  • Translational

    • Combined PARP1-Targeted Nuclear Contrast and Reflectance Contrast Enhance Confocal Microscopic Detection of Basal Cell Carcinoma
      You have access
      Combined PARP1-Targeted Nuclear Contrast and Reflectance Contrast Enhance Confocal Microscopic Detection of Basal Cell Carcinoma
      Aditi Sahu, Jose Cordero, Xiancheng Wu, Susanne Kossatz, Ucalene Harris, Paula Demetrio Desouza Franca, Nicholas R. Kurtansky, Niasia Everett, Stephen Dusza, Jilliana Monnier, Piyush Kumar, Christi Fox, Christian Brand, Sheryl Roberts, Kivanc Kose, William Phillips, Erica Lee, Chih-Shan Jason Chen, Anthony Rossi, Kishwer Nehal, Melissa Pulitzer, Caterina Longo, Allan Halpern, Thomas Reiner, Milind Rajadhyaksha and Manu Jain
      Journal of Nuclear Medicine June 1, 2022, 63 (6) 912-918; DOI: https://doi.org/10.2967/jnumed.121.262600

AI/Advanced Image Analysis

  • Effects of Tracer Uptake Time in Non–Small Cell Lung Cancer <sup>18</sup>F-FDG PET Radiomics
    Open Access
    Effects of Tracer Uptake Time in Non–Small Cell Lung Cancer 18F-FDG PET Radiomics
    Guilherme D. Kolinger, David Vállez García, Gerbrand Maria Kramer, Virginie Frings, Gerben J.C. Zwezerijnen, Egbert F. Smit, Adrianus Johannes de Langen, Irène Buvat and Ronald Boellaard
    Journal of Nuclear Medicine June 1, 2022, 63 (6) 919-924; DOI: https://doi.org/10.2967/jnumed.121.262660

Neurology

  • Clinical

    • Predicting the Outcome of Epilepsy Surgery by Covariance Pattern Analysis of Ictal Perfusion SPECT
      You have access
      Predicting the Outcome of Epilepsy Surgery by Covariance Pattern Analysis of Ictal Perfusion SPECT
      Jila Taherpour, Mariam Jaber, Berthold Voges, Ivayla Apostolova, Thomas Sauvigny, Patrick M. House, Michael Lanz, Matthias Lindenau, Susanne Klutmann, Tobias Martens, Stefan Stodieck and Ralph Buchert
      Journal of Nuclear Medicine June 1, 2022, 63 (6) 925-930; DOI: https://doi.org/10.2967/jnumed.121.262702
    • BRIEF COMMUNICATION

      • Relationship Between <sup>18</sup>F-Flortaucipir Uptake and Histologic Lesion Types in 4-Repeat Tauopathies
        You have access
        Relationship Between 18F-Flortaucipir Uptake and Histologic Lesion Types in 4-Repeat Tauopathies
        Keith A. Josephs, Nirubol Tosakulwong, Stephen D. Weigand, Marina Buciuc, Val J. Lowe, Dennis W. Dickson and Jennifer L. Whitwell
        Journal of Nuclear Medicine June 1, 2022, 63 (6) 931-935; DOI: https://doi.org/10.2967/jnumed.121.262685
  • Translational

    • First-in-Humans Brain PET Imaging of the GluN2B-Containing <em>N</em>-methyl-<span class="sc">d</span>-aspartate Receptor with (<em>R</em>)-<sup>11</sup>C-Me-NB1
      You have access
      First-in-Humans Brain PET Imaging of the GluN2B-Containing N-methyl-d-aspartate Receptor with (R)-11C-Me-NB1
      Lucas Rischka, Chrysoula Vraka, Verena Pichler, Sazan Rasul, Lukas Nics, Gregor Gryglewski, Patricia Handschuh, Matej Murgaš, Godber M. Godbersen, Leo R. Silberbauer, Jakob Unterholzner, Christoph Wotawa, Achi Haider, Hazem Ahmed, Roger Schibli, Thomas Mindt, Markus Mitterhauser, Wolfgang Wadsak, Andreas Hahn, Rupert Lanzenberger, Marcus Hacker and Simon M. Ametamey
      Journal of Nuclear Medicine June 1, 2022, 63 (6) 936-941; DOI: https://doi.org/10.2967/jnumed.121.262427
    • Synaptic Vesicle Glycoprotein 2A Is Affected in the Central Nervous System of Mice with Huntington Disease and in the Brain of a Human with Huntington Disease Postmortem
      Open Access
      Synaptic Vesicle Glycoprotein 2A Is Affected in the Central Nervous System of Mice with Huntington Disease and in the Brain of a Human with Huntington Disease Postmortem
      Daniele Bertoglio, Jeroen Verhaeghe, Leonie Wyffels, Alan Miranda, Sigrid Stroobants, Ladislav Mrzljak, Celia Dominguez, Mette Skinbjerg, Jonathan Bard, Longbin Liu, Ignacio Munoz-Sanjuan and Steven Staelens
      Journal of Nuclear Medicine June 1, 2022, 63 (6) 942-947; DOI: https://doi.org/10.2967/jnumed.121.262709

Cardiovascular

  • Clinical

    • BRIEF COMMUNICATION

      • Feasibility of In Vivo Imaging of Fibroblast Activation Protein in Human Arterial Walls
        You have access
        Feasibility of In Vivo Imaging of Fibroblast Activation Protein in Human Arterial Walls
        Meiqi Wu, Jing Ning, Jingle Li, Zhichao Lai, Ximin Shi, Haiqun Xing, Marcus Hacker, Bao Liu, Li Huo and Xiang Li
        Journal of Nuclear Medicine June 1, 2022, 63 (6) 948-951; DOI: https://doi.org/10.2967/jnumed.121.262863

Radiochemistry

  • Basic

    • FEATURED BASIC SCIENCE ARTICLE

      • Albumin Binder–Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy
        Open Access
        Albumin Binder–Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy
        Mengxin Xu, Pu Zhang, Jie Ding, Junyi Chen, Li Huo and Zhibo Liu
        Journal of Nuclear Medicine June 1, 2022, 63 (6) 952-958; DOI: https://doi.org/10.2967/jnumed.121.262533

Physics and instrumentation

  • Clinical

    • Feasibility of Acquisitions Using Total-Body PET/CT with an Ultra-Low <sup>18</sup>F-FDG Activity
      Open Access
      Feasibility of Acquisitions Using Total-Body PET/CT with an Ultra-Low 18F-FDG Activity
      Yan Hu, Guobing Liu, Haojun Yu, Ying Wang, Chenwei Li, Hui Tan, Shuguang Chen, Jianying Gu and Hongcheng Shi
      Journal of Nuclear Medicine June 1, 2022, 63 (6) 959-965; DOI: https://doi.org/10.2967/jnumed.121.262038

Letters to the Editor

  • You have access
    The Will Rogers Phenomenon and PSMA PET/CT
    Nicholas C. Friedman and Edward Hines
    Journal of Nuclear Medicine June 1, 2022, 63 (6) 966; DOI: https://doi.org/10.2967/jnumed.121.263556

Departments

  • Book Review

    • You have access
      Nuclear Medicine Textbook: Methodology and Clinical Applications
      Hossein Jadvar
      Journal of Nuclear Medicine June 1, 2022, 63 (6) 967; DOI: https://doi.org/10.2967/jnumed.121.263612

SNMMI Newsline

  • You have access
    SNMMI Newsline
    Journal of Nuclear Medicine June 1, 2022, 63 (6) 13N-35N;
  • You have access
    JNM Editors’ Choice Awards for 2021
    Journal of Nuclear Medicine June 1, 2022, 63 (6) 13N;
  • You have access
    Outstanding JNMT Articles for 2021
    Journal of Nuclear Medicine June 1, 2022, 63 (6) 13N;
  • You have access
    SNMMI Leadership Update: Putting Patients First: A Year in Review
    Richard L. Wahl
    Journal of Nuclear Medicine June 1, 2022, 63 (6) 14N;
  • You have access
    SNMMI Procedure Standard/EANM Practice Guideline for Nuclear Medicine Evaluation and Therapy of Differentiated Thyroid Cancer: Abbreviated Version
    Anca M Avram, Luca Giovanella, Bennett Greenspan, Susan A. Lawson, Markus Luster, Douglas Van Nostrand, Justin G. Peacock, Petra Petranović Ovčariček, Edward Silberstein, Mark Tulchinsky, Frederik A. Verburg and Alexis Vrachimis
    Journal of Nuclear Medicine June 1, 2022, 63 (6) 15N-35N;
Back to top
PreviousNext

In this issue

Journal of Nuclear Medicine: 63 (6)
Journal of Nuclear Medicine
Vol. 63, Issue 6
June 1, 2022
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)

Issue highlights

  • Head-to-Head Comparison of 68Ga-PSMA-11 PET/CT and mpMRI with a Histopathology Gold Standard in the Detection, Intraprostatic Localization, and Determination of Local Extension of Primary Prostate Cancer: Results from a Prospective Single-Center Imaging Trial
  • Albumin Binder–Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy
Sign up for alerts

Jump to

  • This Month in JNM
  • Editor's Page
  • Commentary
  • Discussions with Leaders
  • Issues and Controversies
  • Editorial
  • The State of The Art
  • Continuing Education
  • Hot Topics
  • Theranostics
    • Clinical
      • FEATURED ARTICLE OF THE MONTH
      • SPECIAL CONTRIBUTION
    • Translational
      • INVITED PERSPECTIVE
  • Oncology
    • Clinical
      • INVITED PERSPECTIVE
    • Translational
  • AI/Advanced Image Analysis
  • Neurology
    • Clinical
      • BRIEF COMMUNICATION
    • Translational
  • Cardiovascular
    • Clinical
      • BRIEF COMMUNICATION
  • Radiochemistry
    • Basic
      • FEATURED BASIC SCIENCE ARTICLE
  • Physics and instrumentation
    • Clinical
  • Letters to the Editor
  • Departments
    • Book Review
  • SNMMI Newsline
  • Most Cited
  • Most Read
Loading
  • MIRD Pamphlet No. 28, Part 1: MIRDcalc—A Software Tool for Medical Internal Radiation Dosimetry
  • Absorbed Dose–Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [177Lu]Lu-DOTATATE: One Step Closer to Personalized Medicine
  • Prediction of 177Lu-DOTATATE PRRT Outcome Using Multimodality Imaging in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results from a Prospective Phase II LUMEN Study
  • Renal and Multiorgan Safety of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy
  • High-Temporal-Resolution Lung Kinetic Modeling Using Total-Body Dynamic PET with Time-Delay and Dispersion Corrections
More...
SNMMI

© 2025 SNMMI

Powered by HighWire